Figure 2 from Phase I Study of Simlukafusp Alfa (Fap-Il2v) with or Without Atezolizumab in Japanese Patients with Advanced Solid Tumors

Mean changes in serum simlukafusp alfa concentrations after administration of (A) simlukafusp alfa 10 mg (n = 3), (B) simlukafusp alfa 15/20 mg (n = 5), or (C) simlukafusp alfa 10 mg + atezolizumab (n = 3) and (D) mean changes in serum atezolizumab concentrations after administration of simlukafusp alfa 10 mg + atezolizumab (n = 3). Error bars represent SD.